Jupiter Neurosciences, Inc. cash flow to debt ratio of -101.78% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Jupiter Neurosciences, Inc.'s free cash flow has decreased 38.42% from $-3.91M last year to $-5.41M, signaling decreasing performance

Jupiter Neurosciences, Inc.'s debt to equity ratio is -1.74, signaling that the company spent its equity and risk bankruptcy.

Jupiter Neurosciences, Inc.'s debt to equity ratio is -1.74, signaling that the company spent its equity and risk bankruptcy.

Jupiter Neurosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Jupiter Neurosciences, Inc.'s interest coverage ratio is -79.49, which means that the company struggles to meet interest obligations, signaling financial risk.

Jupiter Neurosciences, Inc. has insufficient data to evaluate this check.

Jupiter Neurosciences, Inc.'s short-term liabilities of $7.40M exceed its short-term assets of $4.82M, signaling financial risk

Jupiter Neurosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Jupiter Neurosciences, Inc.'s return on equity of 1.14K%, is higher than 15.00%, indicating good performance

Jupiter Neurosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Jupiter Neurosciences, Inc. has insufficient public price history to evaluate earnings stability.

Jupiter Neurosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Jupiter Neurosciences, Inc. has negative free cash flow, indicating cash burn

Jupiter Neurosciences, Inc.'s yearly earnings has decreased 254.35% since last year from $-2.44M to $-8.64M, signaling decreasing performance

Jupiter Neurosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -455.42% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Jupiter Neurosciences, Inc.'s 3-year revenue CAGR of -54.62% is negative, indicating declining revenue over the past 3 years

Jupiter Neurosciences, Inc. has insufficient public price history to evaluate revenue consistency.

Jupiter Neurosciences, Inc. has insufficient public price history to evaluate ROE consistency.

Jupiter Neurosciences, Inc. has insufficient data to evaluate this check.

Jupiter Neurosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Jupiter Neurosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Jupiter Neurosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Jupiter Neurosciences, Inc. has insufficient data to evaluate this check.

Jupiter Neurosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Jupiter Neurosciences, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Jupiter Neurosciences, Inc. has a price-to-sales ratio of 61.74x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue